Philippe Moreau

Philippe Moreau, MD is Head of the Hematology Department at CHU de Nantes (University Hospital of Nantes) and President of the Intergroupe Francophone du Myélome (IFM) — the French-speaking myeloma cooperative group that has produced some of the most influential randomized trials in the field over the past 30 years. Dr. Moreau has been a central figure in defining induction, consolidation, and maintenance strategies for transplant-eligible newly diagnosed myeloma in the modern era. He led or co-led IFM studies establishing VTd (bortezomib, thalidomide, dexamethasone) as a superior induction regimen over VD and as the European standard prior to ASCT, and contributed to IFM 2009 — the landmark IFM/DFCI trial that compared early versus delayed ASCT in the VRd era and demonstrated the continuing role of upfront ASCT even with VRd triplet induction. Dr. Moreau was also a principal investigator on the FORTE trial evaluating carfilzomib-based quadruplets in transplant-eligible myeloma. He has led IFM trials of lenalidomide, bortezomib, and daratumumab-based maintenance strategies, and has contributed to the IMWG consensus criteria for response assessment and MRD evaluation in myeloma. He has published over 450 peer-reviewed manuscripts, is an Associate Editor of Leukemia, and is a recipient of the French Society of Hematology lifetime achievement recognition.